Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men

References

• Morales A, Lunenfeld B; International Society for the Study of the Aging Male. Aging Male. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. Aging Male 2002;5:74–86
   PubMedGoogle Scholar
• Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005;8:56–8
   PubMedGoogle Scholar
• Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5–12
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Kalinchenko S, Tishova Y. Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men – a suggested update. Aging Male 2013;16:143–50
   PubMed Web of Science ®Google Scholar
• Trinick TR, Feneley MR, Welford H, Carruthers M. International web survey shows high prevalence of symptomatic testosterone deficiency in men. Aging Male 2011;14:10–15
   PubMed Web of Science ®Google Scholar
• Wu FC, Tajar A, Beynon JM, et al. EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123–35
   PubMed Web of Science ®Google Scholar
• AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the evaluation and treatment of hypogonadism in adult male patients 2002. Endocr Pract 2002;8:439–56
   Google Scholar
• Lejeune H, Huyghe E, Droupy S. Hypoactive sexual desire and testosterone deficiency in men. Prog Urol 2013;23:621–8
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Arver S, Moncada I, et al. How to help the aging male? Current approaches to hypogonadism in primary care. Aging Male 2012;15:187–97
   PubMed Web of Science ®Google Scholar
• Dohle GR, Arver S, Bettocchi C, et al. EAU 2014 guideline on male hypogonadism. ISBN: 978-90-79754-83-0. Available from: http://www.uroweb.org/gls/pdf/16_Male_Hypogonadism_LR%20II.pdf [last accessed 8 Dec 2014]
   Google Scholar
• Morley JE, Perry III HM, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006;53:424–9
   PubMed Web of Science ®Google Scholar
• Chen W, Liu ZY, Wang LH, et al. Are the Aging Male's Symptoms (AMS) scale and the Androgen Deficiency in the Aging Male (ADAM) questionnaire suitable for the screening of late-onset hypogonadism in aging Chinese men? Aging Male 2013;16:92–6
   PubMed Web of Science ®Google Scholar
• Rabah DM, Altaweel W, Arafa MA. Clinical assessment and validation of an Arabic Aging Male Symptoms questionnaire in patients with androgen deficiency. Aging Male 2011;14:33–6
   PubMed Web of Science ®Google Scholar
• Behre HM, Tammela TL, Arver S, et al. European Testogel Study Team. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypo-gonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male 2012;15:198–207
   PubMed Web of Science ®Google Scholar
• Zengerling F, Schrader AJ, Cronauer MV, et al. The “Aging Males' Symptoms” Scale (AMS): predictive value for lowered circulating androgens. Aging Male 2012;15:253–7
   PubMed Web of Science ®Google Scholar
• Lee CP, Jiang JR, Chen Y, et al. The “Aging Males' Symptoms” (AMS) Scale assesses depression and anxiety. Aging Male 2013;16:97–101
   PubMed Web of Science ®Google Scholar
• Moore C, Huebler D, Zimmermann T, et al. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004;46:80–7
   PubMed Web of Science ®Google Scholar
• Nakamura M, Fujimura T, Nagata M, et al. Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International Index of Erectile Function-5 questionnaires. Aging Male 2012;15:111–14
   PubMed Web of Science ®Google Scholar
• Hermanns-Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol 2004;5:199–203
   PubMed Web of Science ®Google Scholar
• Saad F, Aversa A, Isidori AM, et al. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev 2012;8:131–43
   PubMedGoogle Scholar
• Corona G, Rastrelli G, Vignozzi L, et al. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 2011;25:337–53
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Morelli A, et al. Hypogonadism and metabolic syndrome. J Endocrinol Invest 2011;34:557–67
   PubMed Web of Science ®Google Scholar
• Brunton SA, Sadovsky R. Late-onset male hypogonadism and testosterone replacement therapy in primary care. J Fam Pract 2010;59:1–8
   Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–59
   PubMed Web of Science ®Google Scholar
• Schneider G, Nienhaus K, Gromoll J, et al. Depressive symptoms in ≥50-year-old males and their relation to genetic androgen receptor polymorphism and sex hormone levels in 3 different samples. Am J Geront Psychiatr 2011;19:274–83
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335–43
   PubMed Web of Science ®Google Scholar
• Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762–9
   PubMed Web of Science ®Google Scholar
• Kaplan SA, O'Neill E, Lowe RS, et al. Testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS). Aging Male 2013;16:48–51
   PubMed Web of Science ®Google Scholar
• Schatzl G, Brossner C, Schmid S, et al. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000;55:397–402
   PubMed Web of Science ®Google Scholar
• Higano C. Androgen deprivation therapy: monitoring and managing the complications. Hematol Oncol Clin North Am 2006;20:909–23
   PubMed Web of Science ®Google Scholar
• Choong K, Basaria S. Emerging cardiometabolic complications of androgen deprivation therapy. Aging Male 2010;13:1–9
   PubMed Web of Science ®Google Scholar
• Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238–44
   PubMed Web of Science ®Google Scholar
• Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with non metastatic prostate cancer. J Urol 2006;176:2443–7
   PubMed Web of Science ®Google Scholar
• Mohile SG, Bylow K, Dale W, et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 2007;109:802–10
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76
   PubMed Web of Science ®Google Scholar
• Saad F, Gooren LJ. Late onset hypogonadism of men is not equivalent to the menopause. Maturitas 2014;79:52–7
   PubMed Web of Science ®Google Scholar
• Cattabiani C, Basaria S, Ceda GP, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest 2012;35:104–20
   PubMed Web of Science ®Google Scholar
• Lee DM, Tajar A, Pye SR, et al. The EMAS Study Group. Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol 2012;166:77–85
   PubMed Web of Science ®Google Scholar
• Pilz S, Frisch S, Koertke H, et al. Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res 2011;43:223–5
   PubMed Web of Science ®Google Scholar
• Wehr E, Pilz S, Boehm BO, et al. Association of vitamin D status with serum androgen levels in men. Clin Endocrinol 2010;73:243–8
   PubMed Web of Science ®Google Scholar
• Bremner AP, Feddema P, Leedman PJ, et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab 2012;97:1554–62
   PubMed Web of Science ®Google Scholar
• Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489–99
   PubMed Web of Science ®Google Scholar
• Brochmann H, Bjoro T, Gaarder PI, et al. Prevalence of thyroid dysfunction in elderly subjects. A randomized study in a Norwegian rural community (Naeroy). Acta Endocrinol (Copenh) 1988;117:7–12
   PubMedGoogle Scholar
• Boucai L, Hollowell JG, Surks MI. An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits. Thyroid 2011;21:5–11
   PubMed Web of Science ®Google Scholar
• Dobs AS, Few III WL, Blackman MR, et al. Serum hormones in men with human immunodeficiency virus-associated wasting. J Clin Endocrinol Metab 1996;81:4108–12
   PubMed Web of Science ®Google Scholar
• Khera M, Bhattacharya RK, Blick G, et al. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male 2012;15:14–21
   PubMed Web of Science ®Google Scholar
• Knegtering H, van der Moolen AE, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003;28:109–23
   PubMed Web of Science ®Google Scholar
• Molitch ME. Drugs and prolactin. Pituitary 2008;11:209–18
   PubMed Web of Science ®Google Scholar
• Martens HF, Sheets PK, Tenover JS, et al. Decreased testosterone levels in men with rheumatoid arthritis: effect of low dose prednisone therapy. J Rheumatol 1994;21:1427–31
   PubMed Web of Science ®Google Scholar
• Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med 2013;11:57
   PubMed Web of Science ®Google Scholar
• Aloisi AM, Aurilio C, Bachiocco V, et al. Endocrine consequences of opioid therapy. Psychoneuroendocrinology 2009;34:162–8
   Google Scholar
• Reddy RG, Aung T, Karavitaki N, Wass JAH. Opioid induced hypogonadism. BMJ 2010;341:605–60
   Google Scholar
• Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest 2005;28:14–22
   PubMedGoogle Scholar
• Rosner W, Auchus RJ, Azziz R, et al. Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society Position Statement. J Clin Endocrinol Metab 2007;92:405–13
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Khera M, Maggi M, Zitzmann M. Commentary: who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med 2014;11:1636–45
   PubMed Web of Science ®Google Scholar
• Kacker R, Hornstein A, Morgentaler A. Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population. Aging Male 2013;16:164–8
   PubMed Web of Science ®Google Scholar
• Diver MJ, Imtiaz KE, Ahmad AM, et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003;58:710–17
   PubMed Web of Science ®Google Scholar
• Crawford ED, Barqawi AB, O’Donnell C, Morgentaler A. The association of time of day and serum testosterone concentration in a large screening population. BJU Int 2007;100:509–13
   PubMed Web of Science ®Google Scholar
• Caronia LM, Dwyer AA, Hayden D, et al. Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism. Clin Endocrinol (Oxf) 2013;78:291–6
   PubMed Web of Science ®Google Scholar
• Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011;96:2430–9
   PubMed Web of Science ®Google Scholar
• Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181–6
   PubMed Web of Science ®Google Scholar
• Rajender S, Singh L, Thangaraj K. Phenotypic heterogeneity of mutations in androgen receptor gene. Asian J Androl 2007;9:147–79
   PubMed Web of Science ®Google Scholar
• Zitzmann M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front Horm Res 2009;37:52–61
   PubMed Web of Science ®Google Scholar
• Zitzmann M. Pharmacogenetics of testosterone replacement therapy. Pharmacogenomics 2009;10:1341–9
   PubMed Web of Science ®Google Scholar
• Holm AC, Fredrikson MG, Theodorsson E, et al. Change in testosterone concentrations over time is a better predictor than the actual concentrations for symptoms of late onset hypogonadism. Aging Male 2011;14:249–56
   PubMed Web of Science ®Google Scholar
• Canale D, Caglieresi C, Moschini C, et al. Androgen receptor polymorphism (CAG repeats) and androgenicity. Clin Endocrinol (Oxf) 2005;63:356–61
   PubMed Web of Science ®Google Scholar
• Berglund LH, Prytz HS, Perski A, Svartberg J. Testosterone levels and psychological health status in men from a general population: the Tromsø study. Aging Male 2011;14:37–41
   PubMed Web of Science ®Google Scholar
• Scovell JM, Ramasamy R, Wilken N, et al. Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dL. BJU Int 2014. [Epub ahead of print]. doi: 10.1111/bju.12970
   Google Scholar
• Morgentaler A. Commentary: guideline for male testosterone therapy: a clinician's perspective. J Clin Endocrinol Metab 2007;92:416–17
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72
   PubMed Web of Science ®Google Scholar
• Tajar A, McBeth J, Lee DM, et al. European Male Aging Study Group. Elevated levels of gonadotrophins but not sex steroids are associated with musculoskeletal pain in middle-aged and older European men. Pain 2011;152:1495–501
   PubMed Web of Science ®Google Scholar
• Citron JT, Ettinger B, Rubinoff H, et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol 1996;155:529–33
   PubMed Web of Science ®Google Scholar
• Bunch TJ, Abraham D, Wang S, Meikle AW. Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction. Aging Male 2002;5:38–46
   PubMedGoogle Scholar
• Araujo AB, O'Donnell A, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab 2004;89:5920–6
   PubMed Web of Science ®Google Scholar
• Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest 2005;28:28–31
   PubMedGoogle Scholar
• Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675–85
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, et al. Blast Study Group. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract 2014;68:203–15
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85:2670–7
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male 2012;15:96–102
   PubMed Web of Science ®Google Scholar
• Haider A, Meergans U, Traish A, et al. Progressive improvement of T-scores in men with osteoporosis and subnormal serum testosterone levels upon treatment with testosterone over six years. Int J Endocrinol 2014;2014:496948
   PubMed Web of Science ®Google Scholar
• Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men a meta-analysis. Clin Endocrinol (Oxf) 2005;63:280–93
   PubMed Web of Science ®Google Scholar
• Bhasin S, Calof OM, Storer TW, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006;2:146–59
   PubMedGoogle Scholar
• Rodrıguez-Tolra J, Torremude Bareda J, Del Rio L, et al. Effects of testosterone treatment on body composition in males with testosterone deficiency syndrome. Aging Male 2013;16:184–90
   PubMed Web of Science ®Google Scholar
• Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013;21:1975–81
   PubMed Web of Science ®Google Scholar
• Yassin AA, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obesity 2013;3:73–83
   PubMedGoogle Scholar
• Francomano D, Ilacqua A, Bruzziches R, et al. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014;83:167–74
   PubMed Web of Science ®Google Scholar
• Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with “diabesity”: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol 2014;2014:683515
   PubMed Web of Science ®Google Scholar
• Krasnoff JB, Basaria S, Pencina MJ, et al. Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study. J Clin Endocrinol Metab 2010;95:2790–9
   PubMed Web of Science ®Google Scholar
• Kacker R, Conners W, Zade J, Morgentaler A. Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility. J Urol 2014;191:1072–6
   PubMed Web of Science ®Google Scholar
• Drake MT, Murad MH, Mauck KF, et al. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012;97:1861–70
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johansson H, et al. FRAX and its applications to clinical practice. Bone 2009;44:734–43
   PubMed Web of Science ®Google Scholar
• Watts NB, Adler RA, Bilezikian JP, et al.; Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:1802–22
   PubMed Web of Science ®Google Scholar
• Orwoll E, Lambert LC, Marshall LM, et al. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med 2006;166:2124–31
   PubMedGoogle Scholar
• Zitzmann M, Brune M, Vieth V, Nieschlag E. Monitoring bone density in hypogonadal men by quantitative phalangeal ultrasound. Bone 2002;31:422–9
   PubMedGoogle Scholar
• Corona G, Isidori AM, Buvat J, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 2014;11:1577–92
   PubMed Web of Science ®Google Scholar
• Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94–9
   PubMedGoogle Scholar
• Zitzmann M, Mattern A, Hanisch J, et al. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2013;10:579–88
   PubMed Web of Science ®Google Scholar
• Tan WS, Ng CJ, Khoo EM, et al. The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men's Health Study). Aging Male 2011;14:231–6
   PubMed Web of Science ®Google Scholar
• Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911–17
   PubMed Web of Science ®Google Scholar
• Tajar A, Huhtaniemi IT, O'Neill TW, et al.; EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012;97:1508–16
   PubMed Web of Science ®Google Scholar
• Tsujimura A, Miyagawa Y, Takezawa K, et al. Is low testosterone concentration a risk factor for metabolic syndrome in healthy middle-aged men? Urology 2013;82:814–19
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late onset hypogonadism and metabolic syndrome: results from a 24-months, randomized double blind placebo-controlled study. J Sex Med 2010;7:3495–503
   PubMed Web of Science ®Google Scholar
• Strollo F, Strollo G, More M, et al. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients. Aging Male 2013;16:33–7
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726–33
   PubMed Web of Science ®Google Scholar
• Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hyperten Res 2007;30:1029–34
   PubMed Web of Science ®Google Scholar
• Muller M, van den Beld AW, Bots ML, et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004;109:2074–9
   PubMed Web of Science ®Google Scholar
• Kang SM, Jang Y, Kim JY, et al. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 2002;89:862–4
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Vorona E, Wenk M, et al. Testosterone administration decreases carotid artery intima media thickness as indicator of vascular damage in middle-aged overweight men. J Androl 2008;29:54–5
   Google Scholar
• Herring MJ, Mesbah Oskui P, Hale SL, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. J Am Heart Assoc 2013;2:e000271
   PubMed Web of Science ®Google Scholar
• Nettleship JE, Pugh PJ, Channer KS, et al. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res 2007;39:366–71
   PubMed Web of Science ®Google Scholar
• Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010;73:602–12
   PubMed Web of Science ®Google Scholar
• Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol 2013;217:R25–45
   PubMed Web of Science ®Google Scholar
• Vodo S, Bechi N, Petroni A, et al. Testosterone-induced effects on lipids and inflammation. Mediators Inflamm 2013;2013:183041
   PubMed Web of Science ®Google Scholar
• Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 2014;13:1327–51
   PubMed Web of Science ®Google Scholar
• Tan Robert S, Cook Kelly R, Reilly William G. Testosterone therapy is not associated with higher risk of myocardial infarction or stroke: the low T experience. Presented at American Association of Clinical Endocrinologists 23rd Annual Scientific and Clinical Congress, Las Vegas, Nevada, May 13–18, 2014. Abstract # 1353
   Google Scholar
• Tan Robert S, Cook Kelly R, Reilly William G. Testosterone therapy is not associated with increased cardiovascular risk in study registry. J Men Health 2014;11:139–139
   Google Scholar
• Araujo AB, Dixon JM, Suarez EA, et al. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:3007–19
   PubMed Web of Science ®Google Scholar
• Hyde Z, Norman PE, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease, but not other causes. The Health in Men Study. J Clin Endocrinol Metab 2012;97:179–89
   PubMed Web of Science ®Google Scholar
• Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012;97:2050–8
   PubMed Web of Science ®Google Scholar
• Yeap Bu B. Testosterone therapy and mortality in US veterans. Asian J Androl 2012;14:667–8
   PubMed Web of Science ®Google Scholar
• Wu FC. Caveat emptor: does testosterone treatment reduce mortality in men? J Clin Endocrinol Metab 2012;97:1884–6
   PubMed Web of Science ®Google Scholar
• Zarrouf FA, Artz S, Griffith J, et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract 2009;15:289–305
   PubMed Web of Science ®Google Scholar
• Giltay EJ, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010;7:2572–82
   PubMed Web of Science ®Google Scholar
• Morley JE, Kaiser F, Raum WJ, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci USA 1997;94:7537–42
   PubMed Web of Science ®Google Scholar
• Maggio M, Dall’Aglio E, Lauretani F, et al. The hormonal pathway to cognitive impairment in older men. J Nutr Health Aging 2012;16:40–54
   PubMed Web of Science ®Google Scholar
• Janowsky JS. Thinking with your gonads: testosterone and cognition. Trends Cogn Sci 2006;10:77–82
   PubMed Web of Science ®Google Scholar
• Etgen T, Sander D, Bickel H, Forstl H. Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch Arztebl Int 2011;108:743–50
   PubMed Web of Science ®Google Scholar
• Kim JW, Oh MM, Yoon CY, et al. Nocturnal polyuria and decreased serum testosterone: is there an association in men with lower urinary tract symptoms? Int J Urol 2014;21:518–23
   PubMed Web of Science ®Google Scholar
• Pearl JA, Berhanu D, Francois N, et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol 2013;190:1828–33
   PubMed Web of Science ®Google Scholar
• Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 2011;14:53–8
   PubMed Web of Science ®Google Scholar
• Yassin DJ, El Douaihy Y, Yassin AA, et al. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World J Urol 2014;32:1049–54
   PubMed Web of Science ®Google Scholar
• Pastuszak AW, Pearlman AM, Lai WS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013;190:639–44
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Lipshultz LI, Bennett R, et al. Testosterone therapy in men with untreated prostate cancer. J Urol 2011;185:1256–60
   PubMedGoogle Scholar
• Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310–20
   PubMed Web of Science ®Google Scholar
• Roddam AW, Allen NE, Appleby P, Key TJ; Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170–83
   PubMed Web of Science ®Google Scholar
• Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review. 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560–75
   PubMed Web of Science ®Google Scholar
• Haider A, Zitzmann M, Doros G, et al. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median follow up of 3 registries. J Urol 2014;193:80–6
   PubMedGoogle Scholar
• Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol 2005;60A:1451–7
   Google Scholar
• Morgentaler A, Benesh JA, Denes BS, et al. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J Sex Med 2014;11:2818–25
   PubMed Web of Science ®Google Scholar
• Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482–92
   PubMed Web of Science ®Google Scholar
• Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen in men with and without prostate disease. JAMA 1992;267:2215–20
   PubMed Web of Science ®Google Scholar
• Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469–78
   PubMed Web of Science ®Google Scholar
• Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009;207:318–27
   PubMed Web of Science ®Google Scholar